Latest Post

As 2022 comes to a close, we review Big Molecule Watch’s top five biosimilar regulatory developments of the year:

  • USPTO Outlines New Initiatives Regarding Drug Pricing
  • In July, we reported that Katherine Vidal, the Undersecretary of Commerce for Intellectual Property and Director of the USPTO, published a letter summarizing several initiatives designed in collaboration with